Press
Releases

KINETA_web_hp_redpoint

Press Releases

KINETA_web_hp_redpoint

Kineta Press Releases

  TuHURA has an exclusive right to negotiate to acquire Kineta’s KVA12123 Immuno-Oncology Drug Program Kineta will receive a $5

Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts Favorable clinical safety

  Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts Favorable clinical

  Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts in the

  Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts No dose

  SEATTLE, Feb. 29, 2024 — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel

  SEATTLE, Feb. 22, 2024 — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel

  SEATTLE, Feb. 14, 2024 — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel

  SEATTLE, Feb. 07, 2024 — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel

Disclaimer: The Press Releases on this page are provided for historical purposes only. The information contained in each [press release/news article/event] is accurate only as of the date each was originally issued. Kineta disavows any obligation to update the information after the date of their issuance.